Skip to main content
Erschienen in:

04.05.2022

Treatment of recurrent and persistent Cushing’s disease after first transsphenoidal surgery: lessons learned from an international meta-analysis

verfasst von: Carlos Perez-Vega, Andres Ramos-Fresnedo, Shashwat Tripathi, Ricardo A. Domingo, Krishnan Ravindran, Joao P. Almeida, Jennifer Peterson, Daniel M. Trifiletti, Kaisorn L. Chaichana, Alfredo Quinones-Hinojosa, Susan L. Samson

Erschienen in: Pituitary | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Transsphenoidal surgery (TSS) is the first-line treatment for patients with Cushing’s Disease (CD). Recurrence rates after a first TSS range between 3 and 22% within 3 years. Management of recurrent or persistent CD may include repeat TSS or stereotactic radiosurgery (SRS). We performed a meta-analysis to explore the overall efficacy of TSS and SRS for patients with CD after an initial surgical intervention.

Methods

EMBASE, PubMed, SCOPUS, and Cochrane databases were searched from their dates-of-inception up to December 2021. Inclusion criteria were comprised of patients with an established diagnosis of CD who presented with persistent or biochemically recurrent disease after a first TSS for tumor resection and were treated with a second TSS or SRS.

Results

Search criteria yielded 2,116 studies of which 37 articles from 15 countries were included for analysis. Mean age ranged between 29.9 and 47.9 years, and mean follow-up was 11–104 months. TSS was used in 669 (67.7%) patients, while SRS was used in 320 (32.4%) patients, and remission rates for CD were 59% (95%CI 0.49–0.68) and 74% (95%CI 0.54–0.88), respectively. There was no statistically significant difference in the remission rate between TSS and SRS (P = 0.15). The remission rate of patients with recurrent CD undergoing TSS was 53% (95%CI 0.32–0.73), and for persistent CD was 41% (95%CI 0.28–0.56) (P = 0.36).

Conclusion

Both TSS and SRS are possible approaches for the treatment of recurrent or persistent CD after a first TSS. Our data show that either TSS or SRS represent viable treatment options to achieve remission for this subset of patients.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Fleseriu M, Auchus R, Bancos I, Ben-Shlomo A, Bertherat J, Biermasz NR et al (2021) Consensus on diagnosis and management of Cushing’s disease: a guideline update. Lancet Diabetes Endocrinol 9(12):847–875CrossRefPubMed Fleseriu M, Auchus R, Bancos I, Ben-Shlomo A, Bertherat J, Biermasz NR et al (2021) Consensus on diagnosis and management of Cushing’s disease: a guideline update. Lancet Diabetes Endocrinol 9(12):847–875CrossRefPubMed
2.
Zurück zum Zitat Fleseriu M, Hamrahian AH, Hoffman AR, Kelly DF, Katznelson L (2016) American Association of clinical endocrinologists and American College of Endocrinology disease state clinical review: diagnosis of recurrence in cushing disease. Endocr Pract 22(12):1436–1448CrossRefPubMed Fleseriu M, Hamrahian AH, Hoffman AR, Kelly DF, Katznelson L (2016) American Association of clinical endocrinologists and American College of Endocrinology disease state clinical review: diagnosis of recurrence in cushing disease. Endocr Pract 22(12):1436–1448CrossRefPubMed
3.
Zurück zum Zitat Hofmann BM, Hlavac M, Martinez R, Buchfelder M, Müller OA, Fahlbusch R (2008) Long-term results after microsurgery for Cushing disease: experience with 426 primary operations over 35 years. J Neurosurg 108(1):9–18CrossRefPubMed Hofmann BM, Hlavac M, Martinez R, Buchfelder M, Müller OA, Fahlbusch R (2008) Long-term results after microsurgery for Cushing disease: experience with 426 primary operations over 35 years. J Neurosurg 108(1):9–18CrossRefPubMed
4.
Zurück zum Zitat Valassi E, Biller BM, Swearingen B, Pecori Giraldi F, Losa M, Mortini P et al (2010) Delayed remission after transsphenoidal surgery in patients with Cushing’s disease. J Clin Endocrinol Metab 95(2):601–610CrossRefPubMedPubMedCentral Valassi E, Biller BM, Swearingen B, Pecori Giraldi F, Losa M, Mortini P et al (2010) Delayed remission after transsphenoidal surgery in patients with Cushing’s disease. J Clin Endocrinol Metab 95(2):601–610CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Tritos NA, Biller BM, Swearingen B (2011) Management of Cushing disease. Nat Rev Endocrinol 7(5):279–289CrossRefPubMed Tritos NA, Biller BM, Swearingen B (2011) Management of Cushing disease. Nat Rev Endocrinol 7(5):279–289CrossRefPubMed
6.
Zurück zum Zitat Patil CG, Veeravagu A, Prevedello DM, Katznelson L, Vance ML, Laws ER, Jr (2008) Outcomes after repeat transsphenoidal surgery for recurrent Cushing's disease. Neurosurgery 63(2):266–270; discussion 70–71. Patil CG, Veeravagu A, Prevedello DM, Katznelson L, Vance ML, Laws ER, Jr (2008) Outcomes after repeat transsphenoidal surgery for recurrent Cushing's disease. Neurosurgery 63(2):266–270; discussion 70–71.
7.
Zurück zum Zitat Chee GH, Mathias DB, James RA, Kendall-Taylor P (2001) Transsphenoidal pituitary surgery in Cushing’s disease: can we predict outcome? Clin Endocrinol (Oxf) 54(5):617–626CrossRef Chee GH, Mathias DB, James RA, Kendall-Taylor P (2001) Transsphenoidal pituitary surgery in Cushing’s disease: can we predict outcome? Clin Endocrinol (Oxf) 54(5):617–626CrossRef
8.
Zurück zum Zitat Hofmann BM, Hlavac M, Kreutzer J, Grabenbauer G, Fahlbusch R (2006) Surgical treatment of recurrent Cushing's disease. Neurosurgery 58(6):1108–1118; discussion -18. Hofmann BM, Hlavac M, Kreutzer J, Grabenbauer G, Fahlbusch R (2006) Surgical treatment of recurrent Cushing's disease. Neurosurgery 58(6):1108–1118; discussion -18.
9.
Zurück zum Zitat Hughes JD, Young WF, Chang AY, Link MJ, Garces YI, Laack NN et al (2020) Radiosurgical management of patients with persistent or recurrent cushing disease after prior transsphenoidal surgery: a management algorithm based on a 25-year experience. Neurosurgery 86(4):557–564CrossRefPubMed Hughes JD, Young WF, Chang AY, Link MJ, Garces YI, Laack NN et al (2020) Radiosurgical management of patients with persistent or recurrent cushing disease after prior transsphenoidal surgery: a management algorithm based on a 25-year experience. Neurosurgery 86(4):557–564CrossRefPubMed
10.
Zurück zum Zitat Yuen KCJ (2021) Osilodrostat: a review of recent clinical studies and practical recommendations for its use in the treatment of Cushing disease. Endocr Pract 27(9):956–965CrossRefPubMed Yuen KCJ (2021) Osilodrostat: a review of recent clinical studies and practical recommendations for its use in the treatment of Cushing disease. Endocr Pract 27(9):956–965CrossRefPubMed
11.
Zurück zum Zitat Truong HL, Nellesen D, Ludlam WH, Neary MP (2014) Budget impact of pasireotide for the treatment of Cushing’s disease, a rare endocrine disorder associated with considerable comorbidities. J Med Econ 17(4):288–295CrossRefPubMed Truong HL, Nellesen D, Ludlam WH, Neary MP (2014) Budget impact of pasireotide for the treatment of Cushing’s disease, a rare endocrine disorder associated with considerable comorbidities. J Med Econ 17(4):288–295CrossRefPubMed
12.
Zurück zum Zitat Moher D, Liberati A, Tetzlaff J, Altman DG (2010) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 8(5):336–341CrossRefPubMed Moher D, Liberati A, Tetzlaff J, Altman DG (2010) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 8(5):336–341CrossRefPubMed
13.
Zurück zum Zitat Wagenmakers MA, Netea-Maier RT, van Lindert EJ, Timmers HJ, Grotenhuis JA, Hermus AR (2009) Repeated transsphenoidal pituitary surgery (TS) via the endoscopic technique: a good therapeutic option for recurrent or persistent Cushing’s disease (CD). Clin Endocrinol (Oxf) 70(2):274–280CrossRef Wagenmakers MA, Netea-Maier RT, van Lindert EJ, Timmers HJ, Grotenhuis JA, Hermus AR (2009) Repeated transsphenoidal pituitary surgery (TS) via the endoscopic technique: a good therapeutic option for recurrent or persistent Cushing’s disease (CD). Clin Endocrinol (Oxf) 70(2):274–280CrossRef
14.
Zurück zum Zitat Netea-Maier RT, van Lindert EJ, den Heijer M, van der Eerden A, Pieters GF, Sweep CG et al (2006) Transsphenoidal pituitary surgery via the endoscopic technique: results in 35 consecutive patients with Cushing’s disease. Eur J Endocrinol 154(5):675–684CrossRefPubMed Netea-Maier RT, van Lindert EJ, den Heijer M, van der Eerden A, Pieters GF, Sweep CG et al (2006) Transsphenoidal pituitary surgery via the endoscopic technique: results in 35 consecutive patients with Cushing’s disease. Eur J Endocrinol 154(5):675–684CrossRefPubMed
15.
Zurück zum Zitat Locatelli M, Vance ML, Laws ER (2005) Clinical review: the strategy of immediate reoperation for transsphenoidal surgery for Cushing’s disease. J Clin Endocrinol Metab 90(9):5478–5482CrossRefPubMed Locatelli M, Vance ML, Laws ER (2005) Clinical review: the strategy of immediate reoperation for transsphenoidal surgery for Cushing’s disease. J Clin Endocrinol Metab 90(9):5478–5482CrossRefPubMed
16.
Zurück zum Zitat Feng M, Liu Z, Liu X, Bao X, Yao Y, Deng K et al (2018) Diagnosis and outcomes of 341 patients with Cushing’s disease following transsphenoid surgery: a single-center experience. World Neurosurg 109:e75–e80CrossRefPubMed Feng M, Liu Z, Liu X, Bao X, Yao Y, Deng K et al (2018) Diagnosis and outcomes of 341 patients with Cushing’s disease following transsphenoid surgery: a single-center experience. World Neurosurg 109:e75–e80CrossRefPubMed
17.
Zurück zum Zitat Serban AL, Del Sindaco G, Sala E, Carosi G, Indirli R, Rodari G et al (2020) Determinants of outcome of transsphenoidal surgery for Cushing disease in a single-centre series. J Endocrinol Invest 43(5):631–639CrossRefPubMed Serban AL, Del Sindaco G, Sala E, Carosi G, Indirli R, Rodari G et al (2020) Determinants of outcome of transsphenoidal surgery for Cushing disease in a single-centre series. J Endocrinol Invest 43(5):631–639CrossRefPubMed
18.
Zurück zum Zitat Bodaghabadi M, Riazi H, Aran S, Bitaraf MA, Alikhani M, Alahverdi M et al (2014) Repeated transsphenoidal surgery or gamma knife radiosurgery in recurrent cushing disease after transsphenoidal surgery. J Neurol Surg A Cent Eur Neurosurg 75(2):91–97CrossRefPubMed Bodaghabadi M, Riazi H, Aran S, Bitaraf MA, Alikhani M, Alahverdi M et al (2014) Repeated transsphenoidal surgery or gamma knife radiosurgery in recurrent cushing disease after transsphenoidal surgery. J Neurol Surg A Cent Eur Neurosurg 75(2):91–97CrossRefPubMed
19.
Zurück zum Zitat Kara M, Güdük M, Samanci Y, Yilmaz M, Şengöz M, Peker S (2020) Gamma knife radiosurgery in patients with Cushing’s disease: comparison of aggressive pituitary corticotroph tumor versus corticotroph adenoma. Clin Neurol Neurosurg 197:106151CrossRefPubMed Kara M, Güdük M, Samanci Y, Yilmaz M, Şengöz M, Peker S (2020) Gamma knife radiosurgery in patients with Cushing’s disease: comparison of aggressive pituitary corticotroph tumor versus corticotroph adenoma. Clin Neurol Neurosurg 197:106151CrossRefPubMed
20.
Zurück zum Zitat Pollock BE, Brown PD, Nippoldt TB, Young WF Jr (2008) Pituitary tumor type affects the chance of biochemical remission after radiosurgery of hormone-secreting pituitary adenomas. Neurosurgery 62(6):1271–1276CrossRefPubMed Pollock BE, Brown PD, Nippoldt TB, Young WF Jr (2008) Pituitary tumor type affects the chance of biochemical remission after radiosurgery of hormone-secreting pituitary adenomas. Neurosurgery 62(6):1271–1276CrossRefPubMed
21.
Zurück zum Zitat Sheehan JP, Xu Z, Salvetti DJ, Schmitt PJ, Vance ML (2013) Results of gamma knife surgery for Cushing’s disease: clinical article. J Neurosurg 119(6):1486–1492CrossRefPubMed Sheehan JP, Xu Z, Salvetti DJ, Schmitt PJ, Vance ML (2013) Results of gamma knife surgery for Cushing’s disease: clinical article. J Neurosurg 119(6):1486–1492CrossRefPubMed
22.
Zurück zum Zitat Trifiletti DM, Xu Z, Dutta SW, Quiñones-Hinojosa A, Peterson J, Vance ML et al (2018) Endocrine remission after pituitary stereotactic radiosurgery: differences in rates of response for matched cohorts of cushing disease and acromegaly patients. Int J Radiat Oncol Biol Phys 101(3):610–617CrossRefPubMed Trifiletti DM, Xu Z, Dutta SW, Quiñones-Hinojosa A, Peterson J, Vance ML et al (2018) Endocrine remission after pituitary stereotactic radiosurgery: differences in rates of response for matched cohorts of cushing disease and acromegaly patients. Int J Radiat Oncol Biol Phys 101(3):610–617CrossRefPubMed
23.
Zurück zum Zitat Moore JM, Sala E, Amorin A, Martinez H Jr, Bhowmik AC, Chang SD et al (2018) CyberKnife radiosurgery in the multimodal management of patients with cushing disease. World Neurosurg 112:e425–e430CrossRefPubMed Moore JM, Sala E, Amorin A, Martinez H Jr, Bhowmik AC, Chang SD et al (2018) CyberKnife radiosurgery in the multimodal management of patients with cushing disease. World Neurosurg 112:e425–e430CrossRefPubMed
24.
Zurück zum Zitat Petit JH, Biller BM, Yock TI, Swearingen B, Coen JJ, Chapman P et al (2008) Proton stereotactic radiotherapy for persistent adrenocorticotropin-producing adenomas. J Clin Endocrinol Metab 93(2):393–399CrossRefPubMed Petit JH, Biller BM, Yock TI, Swearingen B, Coen JJ, Chapman P et al (2008) Proton stereotactic radiotherapy for persistent adrenocorticotropin-producing adenomas. J Clin Endocrinol Metab 93(2):393–399CrossRefPubMed
25.
Zurück zum Zitat Hofmann BM, Fahlbusch R (2006) Treatment of Cushing's disease: a retrospective clinical study of the latest 100 cases. In: Laws Jr ER, Sheehan JP, editors. Front Hormone Res 158–184 Hofmann BM, Fahlbusch R (2006) Treatment of Cushing's disease: a retrospective clinical study of the latest 100 cases. In: Laws Jr ER, Sheehan JP, editors. Front Hormone Res 158–184
26.
Zurück zum Zitat Dimopoulou C, Schopohl J, Rachinger W, Buchfelder M, Honegger J, Reincke M et al (2014) Long-term remission and recurrence rates after first and second transsphenoidal surgery for Cushing’s disease: care reality in the Munich Metropolitan Region. Eur J Endocrinol 170(2):283–292CrossRefPubMed Dimopoulou C, Schopohl J, Rachinger W, Buchfelder M, Honegger J, Reincke M et al (2014) Long-term remission and recurrence rates after first and second transsphenoidal surgery for Cushing’s disease: care reality in the Munich Metropolitan Region. Eur J Endocrinol 170(2):283–292CrossRefPubMed
27.
Zurück zum Zitat Burke WT, Penn DL, Repetti CS, Iuliano S, Laws ER (2019) Outcomes after repeat transsphenoidal surgery for recurrent Cushing disease: updated. Neurosurgery 85(6):E1030–E1036CrossRefPubMed Burke WT, Penn DL, Repetti CS, Iuliano S, Laws ER (2019) Outcomes after repeat transsphenoidal surgery for recurrent Cushing disease: updated. Neurosurgery 85(6):E1030–E1036CrossRefPubMed
28.
Zurück zum Zitat Almeida JP, de Andrade E, Reghin-Neto M, Radovanovic I, Recinos PF, Kshettry VR. From above and below: the microsurgical anatomy of endoscopic endonasal and transcranial microsurgical approaches to the parasellar region. World Neurosurg 2021. Almeida JP, de Andrade E, Reghin-Neto M, Radovanovic I, Recinos PF, Kshettry VR. From above and below: the microsurgical anatomy of endoscopic endonasal and transcranial microsurgical approaches to the parasellar region. World Neurosurg 2021.
29.
Zurück zum Zitat Sheehan JM, Vance ML, Sheehan JP, Ellegala DB, Laws ER Jr (2000) Radiosurgery for Cushing’s disease after failed transsphenoidal surgery. J Neurosurg 93(5):738–742CrossRefPubMed Sheehan JM, Vance ML, Sheehan JP, Ellegala DB, Laws ER Jr (2000) Radiosurgery for Cushing’s disease after failed transsphenoidal surgery. J Neurosurg 93(5):738–742CrossRefPubMed
30.
Zurück zum Zitat Espinosa-de-Los-Monteros AL, Sosa-Eroza E, Espinosa E, Mendoza V, Arreola R, Mercado M (2017) Long-term outcome of the different treatment alternatives for recurrent and persistent Cushing disease. Endocr Pract 23(7):759–767CrossRefPubMed Espinosa-de-Los-Monteros AL, Sosa-Eroza E, Espinosa E, Mendoza V, Arreola R, Mercado M (2017) Long-term outcome of the different treatment alternatives for recurrent and persistent Cushing disease. Endocr Pract 23(7):759–767CrossRefPubMed
31.
Zurück zum Zitat Alahmadi H, Cusimano MD, Woo K et al (2013) Impact of technique on cushing disease outcome using strict remission criteria. Can J Neurol Sci 40(3):334–341CrossRefPubMed Alahmadi H, Cusimano MD, Woo K et al (2013) Impact of technique on cushing disease outcome using strict remission criteria. Can J Neurol Sci 40(3):334–341CrossRefPubMed
32.
Zurück zum Zitat Benveniste RJ, King WA, Walsh J, Lee JS, Delman BN, Post KD (2005) Repeated transsphenoidal surgery to treat recurrent or residual pituitary adenoma. J Neurosurg 102(6):1004–1012CrossRefPubMed Benveniste RJ, King WA, Walsh J, Lee JS, Delman BN, Post KD (2005) Repeated transsphenoidal surgery to treat recurrent or residual pituitary adenoma. J Neurosurg 102(6):1004–1012CrossRefPubMed
33.
Zurück zum Zitat Brichard C, Costa E, Fomekong E, Maiter D, Raftopoulos C (2018) Outcome of transsphenoidal surgery for Cushing disease: a single-center experience over 20 years. World Neurosurg 119:e106–e117CrossRefPubMed Brichard C, Costa E, Fomekong E, Maiter D, Raftopoulos C (2018) Outcome of transsphenoidal surgery for Cushing disease: a single-center experience over 20 years. World Neurosurg 119:e106–e117CrossRefPubMed
34.
Zurück zum Zitat Blevins LS Jr, Christy JH, Khajavi M, Tindall GT (1998) Outcomes of therapy for Cushing’s disease due to adrenocorticotropin-secreting pituitary macroadenomas. J Clin Endocrinol Metab 83(1):63–67PubMed Blevins LS Jr, Christy JH, Khajavi M, Tindall GT (1998) Outcomes of therapy for Cushing’s disease due to adrenocorticotropin-secreting pituitary macroadenomas. J Clin Endocrinol Metab 83(1):63–67PubMed
35.
Zurück zum Zitat Carroll TB, Javorsky BR, Findling JW (2016) Postsurgical recurrent cushing disease: clinical benefit of early intervention in patients with normal urinary free cortisol. Endocr Pract 22(10):1216–1223CrossRefPubMed Carroll TB, Javorsky BR, Findling JW (2016) Postsurgical recurrent cushing disease: clinical benefit of early intervention in patients with normal urinary free cortisol. Endocr Pract 22(10):1216–1223CrossRefPubMed
36.
Zurück zum Zitat Dai C, Liang S, Liu X et al (2020) Outcomes of transsphenoidal surgery in cushing disease patients with negative pituitary magnetic resonance imaging findings: a single-center experience. Endocr Pract 26(11):1320–1330CrossRefPubMed Dai C, Liang S, Liu X et al (2020) Outcomes of transsphenoidal surgery in cushing disease patients with negative pituitary magnetic resonance imaging findings: a single-center experience. Endocr Pract 26(11):1320–1330CrossRefPubMed
37.
Zurück zum Zitat Fomekong E, Maiter D, Grandin C, Raftopoulos C (2009) Outcome of transsphenoidal surgery for Cushing’s disease: a high remission rate in ACTH-secreting macroadenomas. Clin Neurol Neurosurg 111(5):442–449CrossRefPubMed Fomekong E, Maiter D, Grandin C, Raftopoulos C (2009) Outcome of transsphenoidal surgery for Cushing’s disease: a high remission rate in ACTH-secreting macroadenomas. Clin Neurol Neurosurg 111(5):442–449CrossRefPubMed
38.
Zurück zum Zitat Friedman RB, Oldfield EH, Nieman LK et al (1989) Repeat transsphenoidal surgery for Cushing’s disease. J Neurosurg 71(4):520–527CrossRefPubMed Friedman RB, Oldfield EH, Nieman LK et al (1989) Repeat transsphenoidal surgery for Cushing’s disease. J Neurosurg 71(4):520–527CrossRefPubMed
39.
Zurück zum Zitat Hameed N, Yedinak CG, Brzana J et al (2013) Remission rate after transsphenoidal surgery in patients with pathologically confirmed Cushing’s disease, the role of cortisol, ACTH assessment and immediate reoperation: a large single center experience. Pituitary 16(4):452–458CrossRefPubMed Hameed N, Yedinak CG, Brzana J et al (2013) Remission rate after transsphenoidal surgery in patients with pathologically confirmed Cushing’s disease, the role of cortisol, ACTH assessment and immediate reoperation: a large single center experience. Pituitary 16(4):452–458CrossRefPubMed
40.
Zurück zum Zitat Honegger J, Schmalisch K, Beuschlein F et al (2012) Contemporary microsurgical concept for the treatment of Cushing’s disease: endocrine outcome in 83 consecutive patients. Clin Endocrinol (Oxf) 76(4):560–567CrossRef Honegger J, Schmalisch K, Beuschlein F et al (2012) Contemporary microsurgical concept for the treatment of Cushing’s disease: endocrine outcome in 83 consecutive patients. Clin Endocrinol (Oxf) 76(4):560–567CrossRef
41.
Zurück zum Zitat Liu X, Dai C, Bao X et al (2021) Treatment and outcomes of recurrent/persistent Cushing’s disease: a single-center experience. Ann Palliat Med 10(3):2494–2504CrossRefPubMed Liu X, Dai C, Bao X et al (2021) Treatment and outcomes of recurrent/persistent Cushing’s disease: a single-center experience. Ann Palliat Med 10(3):2494–2504CrossRefPubMed
42.
Zurück zum Zitat Martinez Ortega AJ, Venegas-Moreno E, Dios E et al (2019) Surgical outcomes and comorbidities in Cushing disease: 30 years of experience in a referral center. World Neurosurgery 122:e436–e442CrossRefPubMed Martinez Ortega AJ, Venegas-Moreno E, Dios E et al (2019) Surgical outcomes and comorbidities in Cushing disease: 30 years of experience in a referral center. World Neurosurgery 122:e436–e442CrossRefPubMed
43.
Zurück zum Zitat Mayberg M, Reintjes S, Patel A et al (2018) Dynamics of postoperative serum cortisol after transsphenoidal surgery for Cushing’s disease: implications for immediate reoperation and remission. J Neurosurg 129(5):1268–1277CrossRefPubMed Mayberg M, Reintjes S, Patel A et al (2018) Dynamics of postoperative serum cortisol after transsphenoidal surgery for Cushing’s disease: implications for immediate reoperation and remission. J Neurosurg 129(5):1268–1277CrossRefPubMed
44.
Zurück zum Zitat Ram Z, Nieman LK, Cutler GB Jr, Chrousos GP, Doppman JL, Oldfield EH (1994) Early repeat surgery for persistent Cushing’s disease. J Neurosurg 80(1):37–45CrossRefPubMed Ram Z, Nieman LK, Cutler GB Jr, Chrousos GP, Doppman JL, Oldfield EH (1994) Early repeat surgery for persistent Cushing’s disease. J Neurosurg 80(1):37–45CrossRefPubMed
45.
Zurück zum Zitat Rollin G, Ferreira NP, Czepielewski MA (2007) Prospective evaluation of transsphenoidal pituitary surgery in 108 patients with Cushing’s disease. Arq Bras Endocrinol Metabol 51(8):1355–1361CrossRefPubMed Rollin G, Ferreira NP, Czepielewski MA (2007) Prospective evaluation of transsphenoidal pituitary surgery in 108 patients with Cushing’s disease. Arq Bras Endocrinol Metabol 51(8):1355–1361CrossRefPubMed
46.
Zurück zum Zitat Shimon I, Ram Z, Cohen ZR, Hadani M (2002) Transsphenoidal surgery for Cushing's disease: endocrinological follow-up monitoring of 82 patients. Neurosurgery 51(1):57–61; discussion 61–52. Shimon I, Ram Z, Cohen ZR, Hadani M (2002) Transsphenoidal surgery for Cushing's disease: endocrinological follow-up monitoring of 82 patients. Neurosurgery 51(1):57–61; discussion 61–52.
47.
Zurück zum Zitat Shirvani M, Motiei-Langroudi R, Sadeghian H (2016) Outcome of microscopic transsphenoidal surgery in Cushing disease: a case series of 96 patients. World Neurosurg 87:170–175CrossRefPubMed Shirvani M, Motiei-Langroudi R, Sadeghian H (2016) Outcome of microscopic transsphenoidal surgery in Cushing disease: a case series of 96 patients. World Neurosurg 87:170–175CrossRefPubMed
48.
Zurück zum Zitat Valderrábano P, Aller J, García-Valdecasas L et al (2014) Results of repeated transsphenoidal surgery in Cushing’s disease Long-term follow-up. Endocrinol Nutr 61(4):176–183CrossRefPubMed Valderrábano P, Aller J, García-Valdecasas L et al (2014) Results of repeated transsphenoidal surgery in Cushing’s disease Long-term follow-up. Endocrinol Nutr 61(4):176–183CrossRefPubMed
Metadaten
Titel
Treatment of recurrent and persistent Cushing’s disease after first transsphenoidal surgery: lessons learned from an international meta-analysis
verfasst von
Carlos Perez-Vega
Andres Ramos-Fresnedo
Shashwat Tripathi
Ricardo A. Domingo
Krishnan Ravindran
Joao P. Almeida
Jennifer Peterson
Daniel M. Trifiletti
Kaisorn L. Chaichana
Alfredo Quinones-Hinojosa
Susan L. Samson
Publikationsdatum
04.05.2022
Verlag
Springer US
Erschienen in
Pituitary / Ausgabe 3/2022
Print ISSN: 1386-341X
Elektronische ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-022-01215-1

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Neu im Fachgebiet Innere Medizin

Vorhofflimmern: Antikoagulation vor Schlaganfall von Vorteil

Erleiden Menschen mit Vorhofflimmern einen ischämischen Schlaganfall, ist dieser weniger schwer, auch sind Infarktgröße und Blutungsrisiko geringer, wenn sie zuvor orale Antikoagulanzien erhalten haben. Die Art der Antikoagulation spielt dabei keine Rolle.

HCL-Systeme bei Typ-1-Diabetes: Blutzuckerkontrolle besser, Risiko für Ketoazidose aber höher

Eine bessere Blutzuckerkontrolle und weniger Fälle von hypoglykämischem Koma, dafür mehr diabetische Ketoazidosen. Dieses HCL-Insulin-Therapie-Profil zeigte sich in einem Vergleich von Hybrid-Closed-Loop(HCL)- und Open-Loop-Systemen bei Typ-I-Diabetes im DPV-Register.

Kein (großer) Schutz vor Kolorektalkarzinom-Rezidiven durch ASS

Die erste Phase-3-Studie zum Nutzen von ASS in der adjuvanten Therapie des kolorektalen Karzinoms ist negativ verlaufen. Das abschließende Urteil über eine Sekundärprävention mit ASS ist trotzdem noch nicht gefallen.

Möglicher Zusatzeffekt von SGLT-2-Hemmern und GLP-1-Analoga bei COPD

Menschen mit Typ-2-Diabetes, die gleichzeitig an COPD leiden, könnten von der Behandlung mit SGLT-2-Hemmern und GLP-1-Rezeptoragonisten doppelt profitieren: Eine Analyse aus den USA deutet auf ein vermindertes Exazerbationsrisiko hin.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.